Expression of Somatostatin Receptor Type 3 (SSTR3) has been reported in brain, breast, eye, gastrointestinal tract, pancreas, and thyroid. G-protein Coupled Receptors (GPCRs) comprise one of the largest families of signaling molecules with more than a thousand members currently predicted to exist. All GPCRs share a structural motif consisting of seven membrane-spanning helices, and exist in both active and inactive forms. An array of activating ligands participate in the conformation of GPCRs which leads to signaling via G-proteins and downstream effectors. Ongoing studies have also shown the vast series of reactions which participate in the negative regulation of GPCRs. This "turn-off" activity has tremendous implications for the physiological action of the cell, and continues to drive pharmacological research for new drug candidates. Two blockbuster drugs which have been developed as GPCR-targeted pharmaceuticals are Zyprexa (Eli Lilly) and Claritin (Schering-Plough) which have multi-billion dollar shares of the mental health and allergy markets, respectively.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: somatostatin receptor 28; somatostatin receptor subtype 3; Somatostatin receptor type 3; SS-3-R; SS3-R; SS3R; SSR-28
Gene Aliases: Smstr28; SS-3-R; SS3-R; SS3R; SSR-28; SSTR; SSTR3